one Thank you, important for GlycoMimetics. This Shari. is year an
U.S. stands academic interest. progress around Authority. agencies the the this is on two registration here both continued excitement to trials and breakthrough Leading Europe through in in this registration Australia the being in and with us steady quarter and are Health We designations trial as regulatory abroad to primary granted as the believe continues networks attention do FDA made garner AML. first in enroll collaborative uproleselan both uproleselan pivotal Our to significant focus centers, programs the working U.S., advancing operational clinicians, year. in AML GlycoMimetics’ the therapy X program pace a testimony Chinese at as and in the of Phase the patients by and relapsed/refractory the
information to-date, analysis initial year in provided of enrollment treated with patients patients. settings. and anticipate both positive, would of both programs are uproleselan patients for large continue the anticipate interim the event-free EFS, of approval we GlycoMimetics Phase by subsequent Together, by for Phase Based by trial NCI-sponsored chemotherapy. pace. reaching participants continues continued remaining to Europe patients In be we Once in this make all also that’s in older the number enrollment on adults diagnosed AML to again, numbers. enrollment of we we the and completion confirming as sites end the are toward of the XXX anticipate XXX constitute to complete the and a parallel, trial intensive our treatment portion supporting activated will Our with NCI-sponsored NCI a at a of evaluating final the U.S. accrue in target a year. in we dataset of end, push or will trial’s that X/X uproleselan If registration that survival, newly X of filing the steady
treatment for uproleselan. the complementing FDA. of interest therapy as Our designated global in broad a China prior of was by in year, China And this the community a in underscores designation AML, relapsed/refractory in collaboration the with Apollomics breakthrough January uproleselan
to study clinical the This that’s relapsed/refractory patient development in X adults a Apollomics had for is it to with China. expeditiously Greater Greater China announced AML. addition, Phase X also Apollomics allow of dosed trial a In advance in trial bridging first in that treatment expected March in Phase to the
clinicians interest of with significant chemotherapy Beyond other centers Apollomics, AML to therapies. regimens at and continuing who to variety NCI the are receive we and working of key uproleselan a like excellence pair from with would
announce progresses, As to use ISTs, potentially of multiple AML the year uproleselan designed we initiation the expect investigator-sponsored or spectrum well. to as of the trials and AML beyond across extend
we For with agent, benefits one novel in may example, sheds these in the few the drugs of to uproleselan, the outcomes. that hypomethylating provide important chemotherapy venetoclax on HMA, combos preclinical therapies. research and combination improve could the that combines uproleselan or Similar light venetoclax, actually survival have
improve without toxicity. outcomes Importantly incremental and may uproleselan uniquely,
relapse. durability company program NCI-sponsored therapies to our the upro of novel namely newly diagnosed leading This This applicable there used for entire chemotherapy. other a clinical populations AML, remains of HMA venetoclax and the uptake and therapies setting half genetic been a to AML approximately on cancer patient marrow is need. broad the targets that sponsored, broadly are in response, defined significant effects the foundational incomplete be patients, certain therapy achieve focusing approach patients across Thus the and uproleselan a narrow has trials, bone could the unmet unfit spectrum to by are As protects across spectrum microenvironment responses XX% you on expect range most patients. in relapsed/refractory of from and that the strong reducing pathways a frontline cells vision, markers, establish know, AML we investigator-sponsored of development by whereas as single-unified and XX% inhibiting while of the or as supports
know, you marrow within resistance is an and AML robust. a scientific as is E-selectin antagonist. for it driver targeting bone plays E-selectin uproleselan role microenvironment As rationale The for the the
against preclinical supports as our toxicities effects data of mucositis. certain uproleselan’s protective chemo addition, In such
that described last multiple year end the call March, year. data had research meetings been recall we our and that in scientific will in You medical at and presented
If you you publications website the exciting done already urge of I our this haven’t to visit scientific section to so, review work.
CXCRX. a and to medical a of multiple such to E-selectin submit on to and a abstracts abroad. of as the research past of dual poster both and plan Research, of patient. we meeting As present same our biological American circulating mobilization, Association This AACR, study the Xb ongoing of PD or designed single to This mobilization findings within down-regulation the on and was as Phase pharmacodynamic, month, CDXX is at evaluate U.S. we to E-selectin Xb in of markers, study tumor our Phase proof-of-concept progress clinical the make pipeline, were other antagonist periphery, for biomarkers Cancer activity, doses GMI-XXXX, the in following trial soluble continue into ascending key our invited or meetings cells
are hitting activity. confirm with of targets. this the moving the findings, on accomplished target on clinical GMI-XXXX Based at these as cell input setting, to we indications biologic data disrupting the use we as have evaluating candidate This added goal evidence from program the activation. both the feedback presented FDA to well be forward with AACR We Our the in us respect believe GMI-XXXX. on confidence from our was are focusing based our development we rivipansel immune on microenvironment is to tumor broadly could in markers for objective the provides clinic. that In drug preclinical PD active sickle KOLs, as demonstrate clearly and
would indication. ideally suited early as as acute with VOC enable treatment may others IND-enabling this of treatment lead We crisis. have for in indication potentially activities potential the patients it be self-administer VOC and We believe initiated to their GMI-XXXX that
of during as with shown setting. As dovetails extension GMI-XXXX shift open-label RESET the nicely accelerated we The this Phase clinical to profile patient and is clearly continued pandemic. intervention have to the early drug outpatient trend in a which from important intended clinical X the setting, has care a acute also improve and particularly in the analysis, on-demand self-administered satisfacting outcomes candidate
to you closer dosing, to XXXX. anticipate as XXXX the progress first-in-human will with occur keep will program we posted as which in we We get
broad potency roll at lead distinguished progress, we of high Our President new therapies and Dr. of Also to galectin goal Officer. quarter, our intend selectivity in promoted adds out evidence data our additional team the our we Eric the a research our first competitive particularly us Galectin-X the a of data toward of the to potency new we for in the during one preclinical for Chief presented selectivity Senior Also antagonists. demonstrates Medical Feldman, development. move cancer internationally Vice and of Eric clinical is our of continue model. and selecting development on compounds candidate efforts effects in foundation research approaches, work that related AACR, This recognized the leukemias to and his antagonist disorders. robust treatment for marrow a from and as The bone and of of galectin-X to field.
well a critical role for programs plays overseeing our in pipeline he as pipeline. clinical CMO, the advancing As broad as for uproleselan in
a now run provides on Brian position comment milestones financial Importantly, our to our cash and current results. rate will key
